Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Non-Current Assets (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Non-Current Assets for 7 consecutive years, with $158.2 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 35.53% to $158.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $741.6 million through Dec 2025, down 18.58% year-over-year, with the annual reading at $158.2 million for FY2025, 35.53% down from the prior year.
  • Non-Current Assets hit $158.2 million in Q4 2025 for Allogene Therapeutics, down from $179.1 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $579.5 million in Q4 2021 to a low of $158.2 million in Q4 2025.
  • Historically, Non-Current Assets has averaged $316.4 million across 5 years, with a median of $269.8 million in 2023.
  • Biggest five-year swings in Non-Current Assets: soared 151.47% in 2021 and later tumbled 49.48% in 2022.
  • Year by year, Non-Current Assets stood at $579.5 million in 2021, then crashed by 49.48% to $292.8 million in 2022, then tumbled by 37.24% to $183.7 million in 2023, then surged by 33.53% to $245.3 million in 2024, then plummeted by 35.53% to $158.2 million in 2025.
  • Business Quant data shows Non-Current Assets for ALLO at $158.2 million in Q4 2025, $179.1 million in Q3 2025, and $187.9 million in Q2 2025.